Cancer Biotech Call For Papers

Cancer=Detect=Prev%PATHOLOGY%UMASS at BANYAN.UMMED.EDU Cancer=Detect=Prev%PATHOLOGY%UMASS at BANYAN.UMMED.EDU
Mon Jun 27 19:54:29 EST 1994


             IMPACT OF BIOTECHNOLOGY ON PREVENTIVE ONCOLOGY AND THERAPY

                         2nd International Symposium on
                 BIOMEDICAL DIAGNOSTIC  &  PROGNOSTIC INDICATORS

                             December  11-13, 1994
                             Boston, Massachusetts

Sponsors : International Society for Preventive Oncology - in cooperation with
The World Health Organization
University of Massachusetts Medical Center
University of Illinois College of Medicine
National Cancer Institute Advanced Biotechnology Center (Genoa)
BASF Bioresearch Corporation

Part A  OVERVIEW
Clinicians, scientists and technicians of medical institutions from around the
world will be meeting to appraise and update knowledge of and experience with
new approaches to risk assessment, early diagnosis and therapy of hematologic 
neoplasms and solid tumors. The symposium has been planned with the goal of 
fostering cooperation between universities, institutes and enterprises 
engaged in the research, development and implementation of advanced 
biotechnologies in laboratory and clinical practice. 

New products, developments and applications will be presented within a
framework of podium sessions, posters and technical displays.  The abstracts
and papers of the experimental and clinical reports will be published in the
peer-review journal, Cancer Detection and Prevention.

The topics for proffered papers include but are not limited to those found in 
Part C of this announcement.

Part B PLENARY PROGRAM

MOLECULAR BIOLOGY
0800-1000, Sunday, Dec 11
* Cell cycle control and regulation of cell proliferation - P Hinds
* Oncogene and tumor suppressor gene mutations - M Schwab
* DNA repair deficiencies in cancer - RA Gatti
* Stromal stem cell interactions - P Quesenberry
* Biology and therapeutic application of normal hematopoietic stem cells -
  LG Terstappen

RISK ASSESSMENT
1530-1730, Sunday, Dec 11
* Molecular biology of precursor lesions, C-erbB2 amplification
* Familial predisposition and genetic susceptibility - JE Garber
* Cofactorial oncogene functions - EJ Stanbridge
* Mutagen sensitivity in carcinogenic susceptibility - MR Spitz
* DNA adducts for identification of exposure to carcinogens and genetic
  biomarkers as intermediate endpoints - GN Wogan
* Molecular pathology (in situ hybridization and PCR) - HJ Wolfe

RISK ASSESSMENT
Biomarkers in preneoplastic and non-neoplastic tissues
0800-1030, Monday, Dec 12
* Systemic morphologic markers - HE Nieburgs
* Morphometric analysis of systemic markers - G Nicolo
* Computerized image cytometry - B Palcic
* p53 mutation in esophageal preinvasive lesions - WP Bennett
* K-ras oncogen in preneoplastic colorectal lesions - Z Ronai
* Oncogene mutations in normal and eding lung cancer diagnosis - DM Shin

THERAPY HEMATOLOGIC NEOPLASMS
1530-1730, Monday, Dec 12
* Clinical use of G-CSF and GM-CSF - JL Gabrilove
* Clinical use of erythropoietin - JL Spivak
* Clinical use of IL6 - EF Winton
* Gene transfer in hematopoietic stem cells - C Dunbar
* Gene transfer in human bone marrow transplantation - H Heslop
* Identification of multidrug resistance genes and selective modulation -
  JL Biedler

THERAPY SOLID TUMORS
0800-1000, Tuesday, Dec 13
* Novel cytotoxic antitumor agents - RA Kamen
* Recombinant immunotoxins - I Pastan
* Genetic modification of TIL for cancer therapy: preclinical and clinical
  studies - P Hwu
* Monoclonal antibodies, drug targeting - I Hellstrom
* Induction and selective modulation of apoptosis - AR Eastman

THERAPY SOLID TUMORS
1530-1730, Tuesday, Dec 13
* Differentiation therapy with new biological agents - SM Lippman
* Engineered vaccines for cancer therapy - GN Callahan
* Angiogenesis and its inhibition - DF Hayes
* Antisense therapy - AM Gewirtz
--------------------------------------------------------------------------
Abstracts of proposed presentations and requests for a detailed list of
program topics may be directed to the program committee via HE Nieburgs MD:

 * Department of Pathology, University of Massachusetts Medical Center
   55 Lake Avenue North, Box 20,  Worcester, MA 01655 USA

 * Telephone (508) 856-1822/1823             Fax (508) 856-1824
 * Internet Address: Cancer Detect Prev at BANYAN.UMMED.EDU
-------------------------------------------------------------------------
Part C  SYMPOSIUM TOPICS...include, but are not limited to...

 1. MOLECULAR BIOLOGY
 * control of homeobox gene development * cell cycle control * proteases in
carcinogenesis * epithelial stromal interactions * protein phosphatases in
carcinogenesis * signaling mechanisms in T-lymphocyte mitogenesis * ras
oncogenes * p53 tumor suppressor gene * growth factor receptor signal
transduction * molecular genetics of tumor initiation and progression

 2. ASSESSMENT OF CANCER RISK AND PROGNOSTIC INDICATORS
 * precursor lesions * familial predisposition * p53 and k-ras mutation
carriers * oncogene amplification * cytogenetic aberrations * DNA adducts  for
identification of exposure to carcinogens * genetic biomarkers as  
intermediate endpoints * molecular genetics of lymphoid neoplasias

 3. EXPERIMENTAL HEMATOPOIESIS
 * biology of normal hematopoietic stem cells * stromal stem cell interaction 
* cytokine regulation * DNA repair deficiencies in cancer * cellular response
mechanisms in the control of hematopoiesis * transcriptional regulation of
hematopoiesis

 4. THERAPY OF HEMATOLOGIC NEOPLASMS
 * clinical use of hematopoietic growth factors * clinical use of
erythropoietin, G-CSF and GM-CSF, IL6 * treatment of leukemia * adult and 
child chemotherapy * biotherapy of acute promyelocytic leukemia * multidrug
resistance modulators

  5. SOLID TUMOR THERAPY
  * cancer chemotherapy * growth factor receptors * novel cytotoxic antitumor
agents * diagnosis and management * recombinant immunotoxins * multidrug
resistance * use of monoclonal antibodies * gene transfer * genetic
modification of tumor infiltrating lymphocytes

  6. OTHER TOPICS
  * clinical application of DNA technology * prognostic testing * detection of
occult neoplastic development * nucleic acid probes in forensic studies and
retrospective pathology * diagnostic application of in situ hybridization and
PCR * identification of inherited germline mutations or deletions of specific
genes * assessment of xenobiotic-induced neoplastic susceptibility
* assessment of response to therapy



More information about the Bionews mailing list